What is a stock summary page? Click here for an overview.
Business Description
Mira Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US60458C1045
Description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 4145 | |||||
Equity-to-Asset | 0.84 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate | 4.81 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 34.81 | |||||
9-Day RSI | 45.09 | |||||
14-Day RSI | 47.77 | |||||
3-1 Month Momentum % | -15.25 | |||||
6-1 Month Momentum % | -13.79 | |||||
12-1 Month Momentum % | -9.09 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.11 | |||||
Quick Ratio | 6.11 | |||||
Cash Ratio | 5.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 3.95 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -262.14 | |||||
ROA % | -224.42 | |||||
ROIC % | -1302.32 | |||||
ROC (Joel Greenblatt) % | -13709.52 | |||||
ROCE % | -201.1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.82 | |||||
Price-to-Tangible-Book | 4.82 | |||||
EV-to-EBIT | -1.7 | |||||
EV-to-EBITDA | -1.7 | |||||
EV-to-FCF | -3.24 | |||||
Price-to-Net-Current-Asset-Value | 4.82 | |||||
Price-to-Net-Cash | 5.05 | |||||
Earnings Yield (Greenblatt) % | -58.82 | |||||
FCF Yield % | -27.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Mira Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.762 | ||
Beta | - | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | 255.47 | ||
14-Day RSI | 47.77 | ||
14-Day ATR ($) | 0.114541 | ||
20-Day SMA ($) | 1.094395 | ||
12-1 Month Momentum % | -9.09 | ||
52-Week Range ($) | 0.51 - 5.01 | ||
Shares Outstanding (Mil) | 16.56 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Mira Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Mira Pharmaceuticals Inc Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
Mira Pharmaceuticals Inc Frequently Asked Questions
What is Mira Pharmaceuticals Inc(MIRA)'s stock price today?
The current price of MIRA is $1.06. The 52 week high of MIRA is $5.01 and 52 week low is $0.51.
When is next earnings date of Mira Pharmaceuticals Inc(MIRA)?
The next earnings date of Mira Pharmaceuticals Inc(MIRA) is 2025-05-13 Est..
Does Mira Pharmaceuticals Inc(MIRA) pay dividends? If so, how much?
Mira Pharmaceuticals Inc(MIRA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |